Law360, New York (October 20, 2009) -- A federal judge has rejected Mutual Pharmaceutical Co. Inc.'s request for a preliminary injunction barring Watson Pharmaceuticals Inc. from claiming that its version of gout treatment colchicine is approved by the U.S. Food and Drug Administration, allegedly in violation of the Lanham Act.
Judge Percy Anderson of the U.S. District Court for the Central District of California ruled Monday that plaintiffs Mutual and AR Scientific Inc., who this summer received orphan drug designation...
